The Levels of Phoenixin-14 and Phoenixin-20 in Patients with Type 2 Diabetes Mellitus

Title:The Levels of Phoenixin-14 and Phoenixin-20 in Patients with Type 2 Diabetes Mellitus

Volume: 24 Issue: 11

Author(s): Ummugulsum Can*, Sadinaz Akdu and Serdar Şahinoğlu

Affiliation:

• Konya City Hospital, Department of Biochemistry, Konya, Turkey

Abstract:

Background: New pathogenesis-related early detection markers are needed to prevent Type 2 Diabetes Mellitus (T2DM).

Objective: We aimed to determine phoenixin (PNX)-14 and PNX-20 levels in T2DM patients and investigate their relationship with diabetes.

Methods: 36 T2DM patients and 36 healthy controls were included in the study, and PNX-14 and PNX-20 levels in blood samples taken from the groups were measured by ELISA method.

Results: Patients' serum PNX-14 and PNX-20 levels were statistically significantly lower than in controls (p <0.001). A negative correlation was detected between PNX-14 and BMI, fasting blood sugar, HbA1c%, and HOMA-IR. A negative correlation was found between PNX-20 and BMI, fasting insulin and glucose, HbA1c%, and HO-MA-IR. A positive correlation was noticed between PNX-14 and PNX-20 levels. In ROC analyses, PNX-14 and PNX-20 performed almost equally in predicting T2DM. In predicting T2DM, the area under the ROC curve for PNX-14 was 0.874 (cutoff value 413.4 ng/L, sensitivity 89 %, specificity 72%), and for PNX-20 was 0.858 (cutoff value 228.7 ng/L, sensitivity 80 %, specificity 83 %).

Conclusion: This study shows that serum PNX measurement may have a high level of evidence in predicting T2DM. PNX, related to pathogenesis, may be useful in diagnosing T2DM and other information to support clinical decision-making.

Cite this article as:

Can Ummugulsum*, Akdu Sadinaz and Şahinoğlu Serdar, The Levels of Phoenixin-14 and Phoenixin-20 in Patients with Type 2 Diabetes Mellitus, Endocrine, Metabolic & Immune Disorders - Drug Targets 2024; 24 (11) . https://dx.doi.org/10.2174/0118715303267256231210060250